As Mirati Therapeutics Inc (NASDAQ:MRTX) Price Rose, Broadfin Capital Llc Lowered Its Position by $30.11 Million

May 17, 2018 - By Steve Marquez

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Corporate LogoDuring 2017 Q4 the big money sentiment increased to 2.21. That’s change of 1.04, from 2017Q3’s 1.17. 10 investors sold all, 9 reduced holdings as MRTX ratio improved. 15 increased stakes while 27 funds bought stakes. Funds hold 17.76 million shares thus 34.00% more from 2017Q3’s 13.25 million shares. Lazard Asset Limited Liability reported 20,383 shs. Blackrock accumulated 0% or 510,362 shs. Citadel Limited Company stated it has 0% of its capital in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Balyasny Asset Mngmt Lc has 12,300 shs. Federated Invsts Pa reported 0% of its capital in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Baker Bros Ltd Partnership owns 2.55M shs. Rock Springs Mngmt Lp holds 0.15% or 180,000 shs. Jennison Assoc Limited Liability Co has 487,599 shs. Pdt Prtnrs Ltd Co stated it has 25,224 shs or 0.01% of all its holdings. Vanguard Grp Inc Inc Inc invested 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Broadfin Ltd Liability Com owns 2.45M shs. Deutsche Fincl Bank Ag holds 1,657 shs or 0% of its capital. Thompson Davis & accumulated 1,500 shs. Ameriprise stated it has 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Raymond James Serv Advisors invested 0% of its capital in Mirati Therapeutics, Inc. (NASDAQ:MRTX).

MRTX had 7 sales and 0 buys since January 11, 2018. This’s net activity of $4.97 million. On Thursday, March 1 Donadio Jamie A sold $1.41 million worth of Mirati Therapeutics, Inc. (NASDAQ:MRTX). BAUM CHARLES M had sold 51,810 shs worth $1.45M on Friday, February 23.

In 2018Q1 SEC filling is reported Kevin Kotler’s stake in Mirati Therapeutics Inc (NASDAQ:MRTX) which was reduced by 41.01%. By selling 1.00M shares Broadfin Capital Llc made the stock Popped Up with 63.01%. At the end of 2018Q1, the hedge fund run by Kevin Kotler held 1.44 million shares of the health care company, valued at $44.33 million, down from 2.45M at the end of the previous reported quarter. For a total of 1.18 million shares it increased its holding in Retrophin Inc (NASDAQ:RTRX) by 1.13M shares in the quarter, and has risen its stake in Horizon Pharma Plc (NASDAQ:HZNP).

Broadfin Capital is located in New York City and was founded by Kevin Kotler. Prior to Broadfin, Kotler could be found working for firms such as ING Barings, the Galleon Group, and ABN AMRO. Broadfin Capital Llc is a New York-based hedge fund that was founded by Kevin Kotler. It had more than $1.26 billion assets under management in December, 2014. Taken from Broadfin Capital latest Adv, the fund reported to have 10 full and part-time employees. Among which 5 performing investment advisory and research functions. The hedge fund had between 1-10 clients.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Ratings Coverage

Total analysts of 5 have positions in Mirati Therapeutics (NASDAQ:MRTX) as follows: 5 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since December 21, 2017 according to StockzIntelligence Inc Mirati Therapeutics has 5 analyst reports. The company rating was maintained by Citigroup on Monday, March 5. On Thursday, December 21 the company was initiated by Cowen & Co. On Wednesday, April 25 the firm has “Buy” rating by H.C. Wainwright given. On Thursday, March 8 the firm has “Buy” rating given by SunTrust.

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products.The firm is worth $1.03 billion. The company's clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.Last it reported negative earnings. The Company’s clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: